Our data support prior studies showing increased TIL at 1–2 weeks after BRAF/MEKi therapy for advanced melanoma [1, 4, 29] and extend those findings by showing that this increase in TIL persists in most patients through the first month, including both CD8 and CD4 T cells. The gene discussed is CD8A; the disease is melanoma.